Opportunistic infections in HIV-infected individuals: Hepatitis C virus

Lancet

Volumn 360, Issue 9333, 2002, Pages 584-586

  Talal, Andrew ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 5071; ANTIVIRUS AGENT; CD4 ANTIGEN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ANEMIA; ANTIBODY SCREENING; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; ECHOGRAPHY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; NEUTROPENIA; NOTE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037167254     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09811-2     Document Type: Note

References (17)

1. Sulkowski M.S. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 30:2000;S77-S84.
2. Eyster M.E., Diamondstone L.S., Lien J.M., Ehmann W.C., Quan S., Goedert J.J. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 6:1993;602-610.
3. Telfer P., Sabin C., Devereux H., Scott F., Dusheiko G., Lee C. The progression of HCV-associated liver disease in a cohort of haemophiliac patients. Br J Haematol. 87:1994;555-661.
4. Benhamou Y., Bochet M., Di Martino V., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients: the Multivirc Group. Hepatology. 30:1999;1054-1148.
5. Puoti M., Bonacini M., Spinetti A., et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and HIV. J Infect Dis. 183:2001;134-137.
6. Soriano V., Sulkowski M., Bergin C., et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS. 16:2002;813-828.
7. Kaplan J.E., Masur H., Holmes K.K. Guidelines for preventing opportunistic infections among HIV-infected persons. MMWR Morb Mortal Wkly Rep. 51:2002;1-46.
8. Dienstag JL. The role of liver biopsy in therapy of chronic hepatitis C. NIH Consensus Development Conference: Management of Hepatitis C. Bethesda, MD, June 10-12, 2002; 81-84.
9. Manns M., McHutchinson J., Gordon S., et al. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomised trial. Lancet. 358:2001;958-965.
10. Fried M, Shiffman M, Reddy RK, et al. Pegylated (40 kDa) interferon alfa-2a (Pegasys®) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter trial. Gastroenterology 2001; 120 (suppl A55): abstr 289.
11. Chung R, Andersen J, Alston B, et al. A randomized, controlled trial of pegylated interferon alpha-a with ribavirin vs. interferon alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071. Ninth conference on retroviruses and opportunistic infections, Seattle, WA, 2002: abstr LB-15.
12. Zhang Z.-X., Millich D.R., Peterson D.L., et al. Interferon-a treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. J Infect Dis. 175:1997;1294-1301.
13. Tam R.C., Pai B., Bard J., et al. Ribavirin polarizes human T cell responses towards a type I cytokine profile. J Hepatol. 30:1999;376-382.
14. Soriano V., Garcia-Samaniego J., Bravo R., et al. Interferon alfa for the treatment of chronic hepatitis C in patients with HIV. Clin Infect Dis. 23:1996;585-591.
15. Pesce A., Taillan B., Rosenthal E., et al. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet. 341:1993;1597.
16. Sulkowski M.S., Moore R.D., Mehta S.A.H., et al. Hepatitis C and progresion of HIV disease. JAMA. 288:2002;199-206.
17. Greub G., Ledergerber B., Battegay M., et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection. Lancet. 356:2000;1800-1805.